CC
VIGL

Centiva Capital’s Vigil Neuroscience VIGL Stock Holding History

Centiva Capital’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,800
Closed -$131K – 2627
2024
Q2 		$131K Buy
+32,800
New +$112K ﹤0.01% 1799

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Centiva Capital's VIGL Position: Q3 2024 in Review

Centiva Capital sold out of Vigil Neuroscience (VIGL) in Q3 2024, closing a stake of 32,800 shares — an estimated $131K sold.

Centiva Capital first reported a position in VIGL in Q2 2024 and held it in 1 quarter. The position peaked at $131K in Q2 2024. 52 funds tracked by Wall St. Rank hold VIGL as of Q3 2024.

  • Centiva Capital reported no remaining Vigil Neuroscience position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 32,800 Vigil Neuroscience shares in Q3 2024, an estimated $131K.
  • Centiva Capital first reported a position in Vigil Neuroscience in Q2 2024 and held it in 1 quarter.
  • Centiva Capital's Vigil Neuroscience position peaked at $131K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.